Faculty profile

Frank Wuest

ResearcherOncologyUniversity of Alberta

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses may be missing. Find their university profile.

Frank Wuest

Researcher

Oncology

Health Sciences

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
43 publications in the last five years, latest in 2026.
Senior (last) author on 19 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (3 CIHR, 3 NSERC), most recently in 2024.
Supervised 2 trainees who won CIHR awards, most recently in 2016.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

128

Publications

139

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Meitner-Auger Electrons Pet Imaging Radiation Biology Radiopharmaceuticals Targeted Radiotherapy Theragnostics Autotaxin Cancer

Latest papers

Novel Hsp90 inhibitors as leads for the development of radiotheragnostics for Meitner-Auger electron therapy.
Bioorganic chemistry · 2026
Neuroendocrine tumour morphology and platelet derived growth factor receptor alpha expression.
Experimental and molecular pathology · 2026
18F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.
Advances in urology · 2026

All 128 publications

Latest funding

133/135La radiopharmaceuticals: Novel radiotheragnostics for PET imaging and Meitner-Auger electron (MAE) therapy in nuclear medicine
CIHR · 2024 · Nominated PI
$906,525
Nano-carriers of novel inhibitors of DNA repair for enhanced therapy in unresectable lung cancer
CIHR · 2024 · Co-investigator
$868,275
Rare Isotopes to Transform Cancer Therapy
SSHRC · 2022 · Co-investigator
$7,944,656

All 22 grants and awards

128 publications.

Novel Hsp90 inhibitors as leads for the development of radiotheragnostics for Meitner-Auger electron therapy.

Kennedy AK, Herrera-Rueda MA, Wilby R, Wuest F, LaPointe P

Bioorganic chemistry2026

DOI: 10.1016/j.bioorg.2026.109522 PMID: 41576901

Neuroendocrine tumour morphology and platelet derived growth factor receptor alpha expression.

Lopez-Campistrous A, Ko YM, Wuest M, Wuest F, McMullen TPW

Experimental and molecular pathology2026

DOI: 10.1016/j.yexmp.2026.105037 PMID: 41812553

18F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.

Stanton Z, Woloschuk B, Tamm A, Hung R, Trivedi A, Kolinsky M, Usmani N, Rowe L, Moore R, Wuest F, Abele J

Advances in urology2026

DOI: 10.1155/aiu/8550174 PMID: 42440684

Sugar Amino Acid Linkers for the Design of [18F]SiFA-PSMA Radioligands.

Gade NR, Wuest M, Bailey JJ, Bhardwaj A, Schirrmacher R, Wuest F

ChemMedChem2026Senior author

DOI: 10.1002/cmdc.70436 PMID: 42587267

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

McNeil BL, Wharton L, Chen CC, Merkens H, Čolović M, Rodríguez-Rodríguez C, Wilson J, Mair S, Zhang C, McDonagh AW, Lin KS, Bénard F, Wuest F, Schaffer P, Ramogida CF

ACS bio & med chem Au2026

DOI: 10.1021/acsbiomedchemau.5c00224 PMID: 41726328

Development and clinical potential of 18F-PSiMA for prostate cancer PET imaging.

Gower-Fry L, Bailey JJ, Wuest M, Pike S, Kostikov A, Dorian A, Wängler C, Wuest F, Schirrmacher R

RSC medicinal chemistry2025

DOI: 10.1039/d5md00275c PMID: 40462771

Optimized Radiosynthesis of the Ketone Body Radioligand (3S)-4-[18F]Fluoro-3-hydroxybutyric Acid ([18F]FBHB) for PET Imaging.

Yuen R, Woodfield JD, Verona M, Bergman CN, Leier S, Wuest M, Wuest F

Organic letters2025Senior author

DOI: 10.1021/acs.orglett.5c02163 PMID: 40498680

Development of a succinyl CoA:3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesity.

Tabatabaei Dakhili SA, Yang K, Al Nebaihi H, Greenwell AA, Wuest M, Woodfield J, Farraj RA, Saed CT, Chan JSF, Bhat RK, Mangra-Bala IA, Shafaati T, Gopal K, Eaton F, Ferrari SR, Wagg CS, Capozzi ME, Campbell JE, Overduin M, Velazquez-Martinez CA, Glover JNM, Wuest F, Brocks DR, Ussher JR

iScience2025

DOI: 10.1016/j.isci.2025.112336 PMID: 40454095

Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells.

Loureiro LR, Pike S, Wuest M, Bergman CN, JØrgensen KR, Bergmann R, Feldmann A, Wuest F, Bachmann M

International journal of molecular sciences2025

DOI: 10.3390/ijms26062686 PMID: 40141329

Comparison of [18F]fluorodeoxyglucose and [68Ga]Gallium DOTA-TATE in patients with active giant cell arteritis.

Clifford AH, Abele J, Hung R, Wuest F, Andersson J, Pike S, Yacyshyn E, Lenza E, Jickling G, Raggi P, Cohen Tervaert JW

EJNMMI reports2025

DOI: 10.1186/s41824-025-00242-y PMID: 40021570

Something wrong or missing on this profile? Suggest a correction

Frank Wuest

Research

Latest papers

Latest funding

Novel Hsp90 inhibitors as leads for the development of radiotheragnostics for Meitner-Auger electron therapy.

Neuroendocrine tumour morphology and platelet derived growth factor receptor alpha expression.

18F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.

Sugar Amino Acid Linkers for the Design&#xa0;of [18F]SiFA-PSMA Radioligands.

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

Development and clinical potential of 18F-PSiMA for prostate cancer PET imaging.

Optimized Radiosynthesis of the Ketone Body Radioligand (3S)-4-[18F]Fluoro-3-hydroxybutyric Acid ([18F]FBHB) for PET Imaging.

Development of a succinyl CoA:3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesity.

Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells.

Comparison of [18F]fluorodeoxyglucose and [68Ga]Gallium DOTA-TATE in patients with active giant cell arteritis.

Rare Isotopes to Transform Cancer Therapy

Novel Radiochemistry with Fluorine-18

Frequent collaborators

John F Valliant

Afsaneh Lavasanifar

Paul LaPointe

Jack Tuszynski

Frederick West

Evangelos Michelakis

Christopher Power

Alexander Thiel

Ratmir Derda

Gopinath Sutendra

Vickie Baracos

Ekaterina Dadachova

Christin Schifani

Michael Kolinsky

Alexey Kostikov

Laurie Ailles

Sanjay Kalra

Nawaid Usmani

Michael Weinfeld

Ronald Moore

Paul Schaffer

Glen Jickling

Todd McMullen

Kuo-Shyan Lin

Francois Benard

Neil Vasdev

Sugar Amino Acid Linkers for the Design of [18F]SiFA-PSMA Radioligands.